Klaus-Heinrich Seifart

Title: Klaus-Heinrich Seifart: Innovator in Gene Therapy

Introduction

Klaus-Heinrich Seifart is a notable inventor based in Marburg, Germany. He has made significant contributions to the field of gene therapy through his innovative work in nucleic acid constructs. His research focuses on the precise regulation of gene expression, which is crucial for advancements in genetic manipulation and therapeutic applications.

Latest Patents

Klaus-Heinrich Seifart holds 1 patent for his invention titled "Nucleic acid constructs containing hybrid promoters." This patent describes a nucleic acid construct designed for the regulated expression of genes in host cells. The construct features at least one mutation that inhibits the proper expression of the gene, along with a second mutation that alleviates this inhibition. This invention has potential applications in preparing pharmaceuticals and treating diseases characterized by excessive cell proliferation.

Career Highlights

Seifart is currently associated with Aventis Pharma Deutschland GmbH, where he continues to contribute to the field of biotechnology. His work has been instrumental in developing innovative solutions for gene therapy, enhancing the understanding of genetic manipulation techniques.

Collaborations

Throughout his career, Klaus-Heinrich Seifart has collaborated with esteemed colleagues, including Rolf Mueller and Hans-Harald Sedlacek. These collaborations have fostered a productive environment for research and innovation in the field of gene therapy.

Conclusion

Klaus-Heinrich Seifart's contributions to gene therapy through his patented inventions highlight his role as a key innovator in the biotechnology sector. His work continues to pave the way for advancements in genetic manipulation and therapeutic applications.